When Pfizer Inc. chief executive officer Jeffrey Kindler explained why he was spending $68 billion to acquire rival Wyeth, he said he was dazzled by the company's "robust pipeline of biopharmaceutical candidates."
Copyright PHILY - Philly.com
When Pfizer Inc. chief executive officer Jeffrey Kindler explained why he was spending $68 billion to acquire rival Wyeth, he said he was dazzled by the company's "robust pipeline of biopharmaceutical candidates."